Correlation of ELISA method with three other automated serological tests for the detection of anti-SARS-CoV-2 antibodies.

Autor: Nguyen NN; Department of Pathology, Baylor Scott and White Health, Temple, Texas, United States of America., Mutnal MB; Department of Pathology, Baylor Scott and White Health, Temple, Texas, United States of America., Gomez RR; Health Texas Provider Network, Baylor Scott and White Health, Dallas, Texas, United States of America., Pham HN; Department of Pathology, Baylor Scott and White Health, Temple, Texas, United States of America., Nguyen LT; Department of Pathology, Baylor Scott and White Health, Temple, Texas, United States of America., Koss W; Department of Pathology, Baylor Scott and White Health, Temple, Texas, United States of America., Rao A; Department of Pathology, Baylor Scott and White Health, Temple, Texas, United States of America., Arroliga AC; Department of Pathology, Baylor Scott and White Health, Temple, Texas, United States of America., Wang L; Department of Pathology, Baylor Scott and White Health, Temple, Texas, United States of America., Wang D; Department of Pathology, Baylor Scott and White Health, Temple, Texas, United States of America., Hua Y; Department of Pathology, Baylor Scott and White Health, Temple, Texas, United States of America., Powell PR; Department of Pathology, Baylor Scott and White Health, Temple, Texas, United States of America., Chen L; Department of Pathology, Baylor Scott and White Health, Temple, Texas, United States of America., McCormack CC; Department of Pathology, Baylor Scott and White Health, Temple, Texas, United States of America., Linz WJ; Department of Pathology, Baylor Scott and White Health, Temple, Texas, United States of America., Mohammad AA; Department of Pathology, Baylor Scott and White Health, Temple, Texas, United States of America.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2020 Oct 06; Vol. 15 (10), pp. e0240076. Date of Electronic Publication: 2020 Oct 06 (Print Publication: 2020).
DOI: 10.1371/journal.pone.0240076
Abstrakt: Public health emergency of SARS-CoV-2 has facilitated diagnostic testing as a related medical countermeasure against COVID-19 outbreak. Numerous serologic antibody tests have become available through an expedited federal emergency use only process. This paper highlights the analytical characteristic of an ELISA based assay by AnshLabs and three random access immunoassay (RAIA) by DiaSorin, Roche, and Abbott that have been approved for emergency use authorization (EUA), at a tertiary academic center in a low disease-prevalence area. The AnshLabs gave higher estimates of sero-prevalence, over the three RAIA methods. For positive results, AnshLabs had 93.3% and 100% agreement with DiaSorin or Abbott and Roche respectively. For negative results, AnshLabs had 74.3% and 78.3% agreement with DiaSorin and Roche or Abbott respectively. All discrepant samples that were positive by AnshLabs and negative by RAIA tested positive by all-in-one step SARS-CoV-2 Total (COV2T) assay performed on the automated Siemens Advia Centaur XPT analyzer. None of these methods, however, are useful in early diagnosis of SARS-CoV-2.
Competing Interests: Baylor Scott and White Health provided support for the study in the form of salaries for all authors. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare. All authors have no other potential competing financial, non-financial, professional, or personal interests.
Databáze: MEDLINE
Externí odkaz: